RARA and acute promyelocytic leukemia: Mechanistically, this treatment triggers the disposal of the promyelocytic leukemia protein (PML)/retinoic acid receptor-alpha (RARalpha) chimeric oncoprotein, which results from the t(15;17) chromosomal translocation and is responsible for the differentiation block of APL blasts.